Quote | Options | News | Analyst Ratings

Last: 16.51

Change: $.00

Percent Change: .00

Volume: 0

Clinical Data, Inc. is focused on the development and commercialization of therapeutics, with two compounds in the areas of central nervous system and cardiovascular disorders. The Company?s late-stage drug candidate is vilazodone, a dual-acting selective and potent serotonin reuptake inhibitor and serotonin receptor 1A (5-HT1A) partial agonist for the treatment of major depressive disorder (MDD). The Company?s second late-stage drug candidate is apadenoson, trademarked Stedivaze, a selective adenosine receptor 2A (AR2A) agonist and coronary vasodilator in Phase III of clinical development for use in nuclear Single Photo Emission Computed Topography (SPECT) myocardial perfusion imaging. The Company also provides the FAMILION family of genetic tests for inherited cardiac syndromes, including cardiac channelopathies and cardiomyopathies. On September 30, 2009, the Company purchased all the assets of Epix Pharmaceuticals, Inc. (Epix).

7:15:00 AM 8/9/2010
Clinical Data, Inc. Reports First Quarter Fiscal Year 2011 Operational and Financial Results
NEWTON, Mass., Aug 09, 2010 (BUSINESS WIRE) -- --- Financing Completed to Support Commercial Preparations for Vilazodone Launch and Phase III Trials of Stedivaze --

8:08:00 AM 7/29/2010
Clinical Data, Inc. to Present at Upcoming Investor Conferences
NEWTON, Mass., Jul 29, 2010 (BUSINESS WIRE) -- Clinical Data, Inc. (CLDA), today announced that Drew Fromkin, President and Chief Executive Officer, will be presenting a corporate overview at three investor conferences:

11:54:00 AM 6/14/2010
Clinical Data, Inc. Announces Closing of $32.0 Million Public Offering Including Full Exercise of Over-Allotment
NEWTON, Mass., Jun 14, 2010 (BUSINESS WIRE) -- Clinical Data, Inc. (CLDA) today announced the closing of its previously announced public offering of 2,237,412 newly issued shares of common stock, including 291,836 shares sold pursuant to the full exercise of an over-allotment option granted to the underwriters, at a price to the public of $14.30 per share. The shares offered by Clinical Data, Inc. exhausted all remaining shares on its existing shelf registration statement. The net proceeds from the sale of the shares, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $30.0 million.

9:12:11 AM 6/14/2010
Clinical Data, Inc. Reports Fourth Quarter and Fiscal Year 2010 Results
NEWTON, Mass., Jun 14, 2010 (BUSINESS WIRE) -- -- Recent Public Offering to Fund Commercial Preparations and Late-stage Programs --

8:31:00 AM 6/9/2010
Clinical Data, Inc. Prices Public Offering of Common Stock
NEWTON, Mass., Jun 09, 2010 (BUSINESS WIRE) -- Clinical Data, Inc. (CLDA) today announced that it has raised gross proceeds of approximately $27.8 million through the public offering of 1,945,576 newly issued shares of its common stock at a price of $14.30 per share. All of the shares are being offered by Clinical Data, Inc., which exhausts all remaining shares on its existing shelf registration statement. The underwriters have an option to purchase up to an additional 291,836 shares to cover over-allotments, which, if purchased, would result in total gross proceeds to the Company of approximately $32.0 million. The offering is expected to close no later than June 14, 2010, subject to the satisfaction of customary closing conditions.

4:05:01 PM 6/8/2010
Clinical Data, Inc. Announces Public Offering of Common Stock
NEWTON, Mass., Jun 08, 2010 (BUSINESS WIRE) -- Clinical Data, Inc. (CLDA) today announced that it intends to offer all remaining shares of common stock on its existing shelf registration statement in an underwritten public offering. BMO Capital Markets Corp. is acting as the sole book running manager, with Wedbush PacGrow Life Sciences and Roth Capital Partners, LLC as co-managers in the offering.